NDRA — ENDRA Life Sciences Inc.

Summary of ENDRA Life Sciences Q2 2024 Earnings Call

1. Key Financial Results and Metrics

• Net Proceeds: Raised $7.3 million from a public offering.
• Cash Position: As of June 30, 2024, cash and cash equivalents stood at $6.4 million, providing a runway into the first half of 2025.
• Operating Expenses: Reduced to $2.2 million from $3 million in Q2 2023, primarily due to a 49% decrease in R&D expenses and a 34% decrease in sales and marketing costs.
• General and Administrative Expenses: Increased slightly by $5,000 due to fundraising costs.

2. Strategic Updates and Business Highlights

• Management Changes: New CFO Richard Jacroux and Head of Regulatory and Clinical Affairs Ziad Rouag have joined the team, bringing experience in technology transformation and regulatory processes.
• Clinical Strategy: Transitioning to a hypothesis-driven, statistically powered prospective clinical trial for the TAEUS liver device, expanding from 20 to approximately 250 subjects across multiple sites.
• Market Focus: Reevaluating the go-to-market strategy, with a shift from hepatology as the primary target market to potentially broader segments such as primary care.
• Cost Management: Implemented a 26% reduction in operating expenses without impacting clinical data collection efforts.

3. Forward Guidance and Outlook

• Clinical Timeline: Aiming to complete clinical work and incorporate data into a de novo submission by mid-2025.
• Strategic Roadmap: Plans to formalize a long-term business strategy and explore additional growth opportunities beyond the initial product offering.
• Implementation Timeline: Clear priorities set for the next 9-12 months to execute clinical studies and prepare for regulatory submissions.

4. Bad News, Challenges, or Points of Concern

• Reverse Stock Split: A one-for-50 reverse stock split was executed to maintain NASDAQ listing, but the stock price remains under $1, raising concerns about market perception.
• High Volume of Warrant Exercises: This contributed to a sharp decline in stock price, which management claims is unrelated to business fundamentals.
• Regulatory and Clinical Risks: The shift to a more complex clinical trial design could introduce delays or challenges in meeting regulatory expectations.

5. Notable Q&A Insights

• Implementation Speed: Management expressed confidence in executing the new strategic path within 9-12 months, focusing on clinical study completion and regulatory submission.
• FDA Submission Timeline: While a specific date for the FDA application was not provided, management indicated a goal for submission by mid-2025 following the completion of clinical studies.

Overall, ENDRA Life Sciences is undergoing significant strategic changes aimed at improving operational efficiency and clinical outcomes, while navigating challenges related to stock performance and regulatory complexities.